Compare SIF & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIF | PLRX |
|---|---|---|
| Founded | 1913 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 81.1M |
| IPO Year | 1995 | 2020 |
| Metric | SIF | PLRX |
|---|---|---|
| Price | $14.41 | $1.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 63.7K | ★ 571.1K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.67 | 29.97 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $111,212,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.54 | $1.09 |
| 52 Week High | $16.28 | $1.95 |
| Indicator | SIF | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 46.43 |
| Support Level | $12.51 | $1.12 |
| Resistance Level | $16.24 | $1.36 |
| Average True Range (ATR) | 1.23 | 0.07 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 27.24 | 50.00 |
SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.